Table 3 Number and percentages of files concordant pre- and post-release of guidelines with advice on risk management strategies provided to carriers
Risk management strategy | Pre-guideline concordant n = 373 n (%) | Post-guideline concordant n = 226 n (%) | Pre- vs post-guideline p-value |
|---|---|---|---|
Breast cancer | |||
 RRBM ≤40 years followed by self-surveillance of chest wall area* | 302/365 (83) | 206/224 (92) | 0.002 |
 Alternatively, in the absence of RRBM, has RRSO been discussed, preferably ≤40 years or before menopause to reduce breast cancer risk?* | 307/356 (86) | 182/218 (84) | 0.37 |
 If breast cancer has been diagnosed in this family < 35 years, has screening been recommended from 5 years prior to earliest age affected?a | 79/128 (62) | 42/63 (67) | 0.51 |
 30–50 years - annual MRI + MMG (if MRI unavailable, annual MMG + US), consider 6-month interval US +CBE* | 257/334 (77) | 182/206 (88) | 0.001 |
  > 50 years - annual MMG+/− US+ CBE* | 138/281(49) | 85/175 (49) | 0.91 |
 If pregnant - no MRI or MMG, consider US | 7/65 (11) | 10/34 (29) | 0.02 |
Risk-reducing medication in women > 35 years (such as tamoxifen or raloxifene)* | 141/373 (38) | 133/226 (59) | < 0.001 |
Ovarian/fallopian tube cancer | |||
 RRSO age ≤ 40 years (if ovaries present)* | 301/356 (85) | 213/218 (98) | < 0.001 |
 Has the patient been told that screening using serum CA125 and/or transvaginal ultrasound (TVU) is not recommended?* | 202/359 (56) | 167/222 (75) | < 0.001 |